Advancing CRISPR-Based Therapeutic Development

The development of novel therapeutic strategies, particularly those utilizing nascent technologies like CRISPR, necessitates a rigorous and protracted clinical trial process. Collaboration with a qualified Contract Development and Manufacturing Organization (CDMO) can streamline this transition from initial discovery to clinical investigation. Aldevron offers comprehensive support for the clinical translation of CRISPR-based therapies. Our services encompass the provision of research-grade and cGMP/clinical-grade nucleases (either off-the-shelf or custom-manufactured), guide RNAs (gRNA) through collaboration with Integrated DNA Technologies (IDT), and HDR donor templates delivered via innovative Nanoplasmid™ vectors. Additionally, Aldevron provides first-in-class ribonucleic protein (RNP) complexing and analytical services, alongside expertise in various delivery modalities such as RNP, mRNA, and viral vectors. This comprehensive service portfolio empowers researchers to navigate the complexities of CRISPR therapy development with greater efficiency.

Explore how a CDMO that manufactures and stocks nucleases at both research and cGMP grades can eliminate the need for custom manufacturing runs, simplify the transition to clinical application, and reduce regulatory filing paperwork.